View Financial HealthBiogen 배당 및 자사주 매입배당 기준 점검 0/6Biogen 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesFirst quarter 2026 earnings released: EPS: US$2.17 (vs US$1.65 in 1Q 2025) May 01Biogen Inc. to Report Q1, 2026 Results on Apr 29, 2026Apr 07Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS) from The Morningside Group Limited and others for $5.6 billion.Apr 02Biogen Inc. Announces Approval Of High Dose Regimen Of Spinraza For Spinal Muscular AtrophyMar 30Biogen Inc. Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus ErythematosusMar 29Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United StatesMar 21Block & Leviton LLP Announces United States District Court for the District of Massachusetts Certifies Class Action on Behalf of Purchasers of Biogen, Inc. SecuritiesMar 19+ 1 more updateBiogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander, Effective End of May 2026Mar 14Biogen Inc. Presents Additional Salanersen Data and Debuts Phase 3 Clinical Trial ProgramMar 12Stoke Therapeutics and Biogen Announce Data Publication for Zorevunersen in Dravet SyndromeMar 06+ 1 more updateBiogen Inc., Annual General Meeting, Jun 09, 2026Feb 12+ 1 more updateFull year 2025 earnings released: EPS: US$8.83 (vs US$11.21 in FY 2024) Feb 08Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular AtrophyFeb 04Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease with No Targeted Treatment OptionsJan 28Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority ReviewJan 26Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyJan 13Biogen Inc. to Report Q4, 2025 Results on Feb 06, 2026Jan 09Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet SyndromeDec 05Eisai Co., Ltd. and Biogen Inc. Present New DataDec 04Eisai Co., Ltd. and Biogen Inc. Announces New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025Dec 03Biogen to Highlight New Lecanemab Data and Scientific Advances At the 18Th Clinical Trials on Alzheimer's Disease ConferenceNov 21Stoke Therapeutics, Inc. and Biogen Inc. Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet SyndromeNov 17Third quarter 2025 earnings released: EPS: US$3.18 (vs US$2.67 in 3Q 2024) Oct 31Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025Oct 22Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet SyndromeOct 10Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's DiseaseOct 07Investor sentiment improves as stock rises 15% Oct 03Biogen Inc. to Report Q3, 2025 Results on Oct 30, 2025Sep 27Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in AustraliaSep 24Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Alcyone Therapeutics, Inc. for $85 million.Sep 19+ 1 more updateC4 Therapeutics Highlights Recent Achievement in Biogen CollaborationSep 04Stoke Therapeutics, Inc. and Biogen Inc. Present Data At the 36Th International Epilepsy Congress That Support the Potential for Zorevunersen to Be the First Disease-Modifying Medicine for Dravet SyndromeSep 03Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy CongressAug 25+ 1 more updateStoke Therapeutics, Inc. and Biogen Inc. Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, A Potential Disease-Modifying Treatment for Dravet SyndromeAug 12New minor risk - Earnings quality Aug 03Second quarter 2025 earnings released: EPS: US$4.33 (vs US$4.01 in 2Q 2024) Aug 01Eisai and Biogen Present Results on Lecanemab Subcutaneous Autoinjector At AAIC 2025Jul 30+ 1 more updateBiogen Inc. Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum DepressionJul 25Stoke Therapeutics, Inc. and Biogen Inc. Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJul 10Biogen Inc. to Report Q2, 2025 Results on Jul 31, 2025Jul 02Biogen Inc. Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous NephropathyJul 01Biogen Inc. Announces New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMAJun 28Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 ResultsJun 25Biogen Inc Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich AtaxiaJun 18UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus ErythematosusJun 12First quarter 2025 earnings released: EPS: US$1.65 (vs US$2.71 in 1Q 2024) May 02Biogen Inc., Annual General Meeting, Jun 17, 2025Apr 29Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European UnionApr 16Investor sentiment deteriorates as stock falls 17% Apr 09BioPharma Credit PLC Enters into Settlement Agreement with BiogenApr 03+ 1 more updateIndependent Director recently sold €1.2m worth of stock Mar 14Eisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's DiseaseFeb 28Full year 2024 earnings released: EPS: US$11.21 (vs US$8.02 in FY 2023) Feb 13Biogen Inc. Provides Earnings Guidance for the Full Year 2025Feb 13High number of new directors Feb 01Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 28Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 14Biogen Inc. Announces Appointment of Adam Feire as Head of Business Development and External InnovationJan 10Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in MexicoDec 05Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South KoreaNov 28Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZNov 19Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s DiseaseNov 15Third quarter 2024 earnings released: EPS: US$2.67 (vs US$0.47 loss in 3Q 2023) Nov 01Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance DosingNov 01Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical AffairsOct 30Biogen Inc. Announces Chief Financial Officer ChangesOct 28+ 1 more updateBiogen Inc. to Report Q3, 2024 Results on Oct 30, 2024Oct 04Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, RespectivelySep 12Second quarter 2024 earnings released: EPS: US$4.01 (vs US$4.09 in 2Q 2023) Aug 02Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European UnionJul 27Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential TremorJul 24Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.Jul 03Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in ChinaJun 28Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024Jun 26Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.May 23+ 1 more updateBiogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisMay 18Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track StatusMay 16Biogen Inc., Annual General Meeting, Jun 20, 2024Apr 28Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRAApr 27First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.69 in 1Q 2023) Apr 24Biogen Inc. Provides Earnings Guidance for the Full Year of 2024Apr 24Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024Apr 11Full year 2023 earnings released: EPS: US$8.02 (vs US$20.97 in FY 2022) Feb 14Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term GrowthJan 31Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024Jan 13CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's AtaxiaDec 16Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIVDec 15Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023Nov 10Third quarter 2023 earnings released: US$0.47 loss per share (vs US$7.86 profit in 3Q 2022) Nov 09Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024Nov 07지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 IDP 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: IDP 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Biogen 배당 수익률 vs 시장IDP의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (IDP)n/a시장 하위 25% (DE)1.6%시장 상위 25% (DE)4.5%업계 평균 (Biotechs)2.3%분석가 예측 (IDP) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 IDP 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 IDP 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 IDP 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: IDP 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/01 21:19종가2026/04/29 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biogen Inc.는 58명의 분석가가 다루고 있습니다. 이 중 23명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David ToungArgus Research CompanyBrian SkorneyBairdEmily FieldBarclays55명의 분석가 더 보기
Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS) from The Morningside Group Limited and others for $5.6 billion.Apr 02
Biogen Inc. Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus ErythematosusMar 29
Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United StatesMar 21
Block & Leviton LLP Announces United States District Court for the District of Massachusetts Certifies Class Action on Behalf of Purchasers of Biogen, Inc. SecuritiesMar 19+ 1 more update
Biogen Inc. Announces Departure of Chief Legal Officer Susan H. Alexander, Effective End of May 2026Mar 14
Stoke Therapeutics and Biogen Announce Data Publication for Zorevunersen in Dravet SyndromeMar 06+ 1 more update
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular AtrophyFeb 04
Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease with No Targeted Treatment OptionsJan 28
Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority ReviewJan 26
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyJan 13
Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet SyndromeDec 05
Eisai Co., Ltd. and Biogen Inc. Announces New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025Dec 03
Biogen to Highlight New Lecanemab Data and Scientific Advances At the 18Th Clinical Trials on Alzheimer's Disease ConferenceNov 21
Stoke Therapeutics, Inc. and Biogen Inc. Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet SyndromeNov 17
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025Oct 22
Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet SyndromeOct 10
Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's DiseaseOct 07
Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in AustraliaSep 24
Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Alcyone Therapeutics, Inc. for $85 million.Sep 19+ 1 more update
Stoke Therapeutics, Inc. and Biogen Inc. Present Data At the 36Th International Epilepsy Congress That Support the Potential for Zorevunersen to Be the First Disease-Modifying Medicine for Dravet SyndromeSep 03
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy CongressAug 25+ 1 more update
Stoke Therapeutics, Inc. and Biogen Inc. Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, A Potential Disease-Modifying Treatment for Dravet SyndromeAug 12
Eisai and Biogen Present Results on Lecanemab Subcutaneous Autoinjector At AAIC 2025Jul 30+ 1 more update
Biogen Inc. Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum DepressionJul 25
Stoke Therapeutics, Inc. and Biogen Inc. Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) CongressJul 10
Biogen Inc. Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous NephropathyJul 01
Biogen Inc. Announces New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMAJun 28
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 ResultsJun 25
Biogen Inc Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich AtaxiaJun 18
UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus ErythematosusJun 12
Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European UnionApr 16
Eisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's DiseaseFeb 28
Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 28
Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's DiseaseJan 14
Biogen Inc. Announces Appointment of Adam Feire as Head of Business Development and External InnovationJan 10
Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in MexicoDec 05
Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South KoreaNov 28
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZNov 19
Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s DiseaseNov 15
Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance DosingNov 01
Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, RespectivelySep 12
Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European UnionJul 27
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential TremorJul 24
Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.Jul 03
Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.May 23+ 1 more update
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisMay 18
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track StatusMay 16
Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRAApr 27
Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term GrowthJan 31
CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's AtaxiaDec 16
Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIVDec 15
Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024Nov 07